News

Inovio Shares Surge After FDA Approves First DNA Medicine for Rare Disease

+2

Health

Inovio Shares Surge After FDA Approves First DNA Medicine for Rare Disease

Maya Lindstrom · 2026-10-31T05:20:43.770Z

This approval should make a real difference for patients facing repeated surgeries for that condition.

8 sourcesUpdated Oct 31, 20261 min read

+2

Inovio Shares Surge After FDA Approves First DNA Medicine for Rare Disease — © IJR

Sponsored

The FDA granted accelerated approval to INOVIO Pharmaceuticals’ VOCERYQ, previously known as INO-3107, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, a rare disease that causes recurring growths in the respiratory tract. The DNA medicine is approved for use with INOVIO’s CELLECTRA 5PSP delivery device, and the company says it is the first FDA-approved DNA medicine. Approval was based on a clinical outcome in which patients required no surgical excisions during the 12 months after treatment; continued approval may depend on a confirmatory study verifying the treatment’s clinical benefit. INOVIO expects the treatment to be available to order and ship in about 60 days, with a full commercial launch anticipated in the first quarter of 2027. The announcement sent INOVIO shares sharply higher in after-hours trading.

Sponsored

In this story:

Sponsored

How it spread

Broke pluang.com · Oct 30, 2:01 PM ETRight +4hCenter +4h8 sources +10h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

How each side headlines it

Left· 0 sources

No left coverage yet — a bubble gap.

Center· 2 sources

“Inovio Pharmaceuticals Gets FDA Accelerated Approval for VOCERYQ”

MarketScreener · Oct 30, 2026

Right· 2 sources

“Inovio surges 280% following FDA approval of Voceryq for rare disease (INO:NASDAQ)”

Seeking Alpha · Oct 30, 2026

Coverage

Sponsored

Comments (2)

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Tom Gallagher⚡71h
The delayed launch until 2027 seems far off but the stock surge shows real promise for DNA medicines.
Maya Lindstrom⚡51h
This approval should make a real difference for patients facing repeated surgeries for that condition.

Sponsored

More on this story

Back to News

Health

Lead Found in Ground Cinnamon Prompts Recall Across 14 States

SLR Food Distribution is recalling Wise Wife Brand Ground Cinnamon sold in 14 states after testing found elevated lead levels. No illnesses have been reported; consumers should not use the cinnamon and should discard it or return it for a refund.

7 sources

Health

FDA Proposes First Formula Nutrient Update in Decades

The FDA has proposed the first major update to U.S. infant-formula nutrition standards in nearly 30 years, revising requirements for vitamins A and D, iodine and manganese while seeking input on whether to require ingredients such as DHA, ARA and L-carnitine. The proposal also includes labeling changes; the agency said most tested formula samples had low or undetectable chemical contaminants and plans further reviews before issuing a final rule.

11 sources

Sponsored

Health

FDA warns Amgen over Vectibix video omitting risk details

The FDA warned Amgen that a submitted promotional video for its colorectal cancer drug Vectibix was misleading because it emphasized benefits while omitting serious safety risks and limits on which patients should receive it, and ordered the company to address the violations. Amgen said an incorrect file was submitted inadvertently, was never publicly distributed, and that the public ad included the required safety information.

8 sources